Table 1 Baseline characteristics according to latent classes
Variables, n (%) | Low complexity class (n = 12,774) | CV risk factors class (n = 9195) | Atherosclerotic class (n = 3328) | Thromboembolic class (n = 2647) | Cardiometabolic class (n = 2462) | High complexity phenotype (n = 2154) | p |
|---|---|---|---|---|---|---|---|
Age, mean (SD) | 69.2 (11.1) | 68.8 (10.4) | 73.1 (9.3) | 72.8 (10.2) | 69.4 (9.3) | 73.3 (8.9) | <0.001 |
 <65 years | 3640/12,774 (28.5) | 2859/9195 (31.1) | 568/3328 (17.1) | 469/2647 (17.7) | 716/2462 (29.1) | 330/2154 (15.3) |  |
 ≥75 years | 4634/12,774 (36.3) | 2993/9195 (32.6) | 1661/3328 (49.9) | 1349/2647 (51.0) | 782/2462 (31.8) | 1064/2154 (49.4) |  |
 65 to <75 years | 4500/12,774 (35.2) | 3343/9195 (36.4) | 1099/3328 (33.0) | 829/2647 (31.3) | 964/2462 (39.2) | 760/2154 (35.3) |  |
Females | 6047/12,774 (47.3) | 4560/9195 (49.6) | 1128/3328 (33.9) | 1188/2647 (44.9) | 934/2462 (37.9) | 940/2154 (43.6) | <0.001 |
Region of recruitment | Â | Â | Â | Â | Â | Â | <0.001 |
 North America | 1943/12,774 (15.2) | 2750/9195 (29.9) | 842/3328 (25.3) | 355/2647 (13.4) | 1240/2462 (50.4) | 901/2154 (41.8) |  |
 Europe | 6099/12,774 (47.7) | 4350/9195 (47.3) | 1395/3328 (41.9) | 1582/2647 (59.8) | 874/2462 (35.5) | 800/2154 (37.1) |  |
 Latin America | 1040/12,774 (8.1) | 673/9195 (7.3) | 178/3328 (5.3) | 161/2647 (6.1) | 120/2462 (4.9) | 72/2154 (3.3) |  |
 Africa/Middle East | 128/12,774 (1.0) | 163/9195 (1.8) | 83/3328 (2.5) | 22/2647 (0.8) | 69/2462 (2.8) | 22/2154 (1.0) |  |
 Asia | 3564/12,774 (27.9) | 1259/9195 (13.7) | 830/3328 (24.9) | 527/2647 (19.9) | 159/2462 (6.5) | 359/2154 (16.7) |  |
Recruited in phase III | 7551/12,774 (59.1) | 5476/9195 (59.6) | 1921/3328 (57.7) | 1594/2647 (60.2) | 1384/2462 (56.2) | 1249/2154 (58.0) | 0.017 |
BMI, kg/m2, median [IQR] | 25.8 [23.3–28.4] | 30.9 [27.0–34.6] | 26.0 [24.0–28.1] | 25.5 [23.2–27.8] | 34.3 [31.7–38.2] | 27.1 [24.2–29.8] | <0.001 |
Paroxysmal AF | 6800/12,774 (53.2) | 5184/9195 (56.4) | 1919/3328 (57.7) | 1538/2647 (58.1) | 1355/2462 (55.0) | 1326/2154 (61.6) | <0.001 |
Comorbidities | Â | Â | Â | Â | Â | Â | Â |
Number of comorbidities, median [IQR] | 1 [1–2] | 3 [2–4] | 4 [3–5] | 3 [2–3] | 5 [5–6] | 5 [4–6] | <0.001 |
 Hypertension | 6759/12,774 (52.9) | 8819/9195 (95.9) | 2829/3328 (85.0) | 1533/2647 (57.9) | 2389/2462 (97.0) | 1865/2154 (86.6) | <0.001 |
 CHF | 3159/12,774 (24.7) | 718/9195 (7.8) | 1563/3328 (47.0) | 188/2647 (7.1) | 1084/2462 (44.0) | 455/2154 (21.1) | <0.001 |
 CAD | 920/12,774 (7.2) | 0/9195 (0.0) | 2873/3328 (86.3) | 48/2647 (1.8) | 1537/2462 (62.4) | 936/2154 (43.5) | <0.001 |
 Diabetes mellitus | 692/12,774 (5.4) | 3272/9195 (35.6) | 1243/3328 (37.3) | 164/2647 (6.2) | 1629/2462 (66.2) | 517/2154 (24.0) | <0.001 |
 PAD | 90/12,774 (0.7) | 0/9195 (0.0) | 391/3328 (11.7) | 28/2647 (1.1) | 239/2462 (9.7) | 237/2154 (11.0) | <0.001 |
 History of stroke/TIA | 12/12,774 (0.1) | 859/9195 (9.3) | 642/3328 (19.3) | 2382/2647 (90.0) | 255/2462 (10.4) | 494/2154 (22.9) | <0.001 |
 Previous bleeding | 333/12,774 (2.6) | 129/9195 (1.4) | 42/3328 (1.3) | 217/2647 (8.2) | 156/2462 (6.3) | 897/2154 (41.6) | <0.001 |
 Abnormal kidney function | 139/12,774 (1.1) | 15/9195 (0.2) | 203/3328 (6.1) | 9/2647 (0.3) | 128/2462 (5.2) | 84/2154 (3.9) | <0.001 |
 Neoplasia | 1040/12,774 (8.1) | 690/9195 (7.5) | 284/3328 (8.5) | 219/2647 (8.3) | 234/2462 (9.5) | 697/2154 (32.4) | <0.001 |
 COPD | 690/12,774 (5.4) | 106/9195 (1.2) | 286/3328 (8.6) | 90/2647 (3.4) | 434/2462 (17.6) | 391/2154 (18.2) | <0.001 |
 Emphysema | 88/12,774 (0.7) | 0/9195 (0.0) | 0/3328 (0.0) | 10/2647 (0.4) | 17/2462 (0.7) | 66/2154 (3.1) | <0.001 |
 Hepatic disease | 217/12,774 (1.7) | 66/9195 (0.7) | 47/3328 (1.4) | 9/2647 (0.3) | 35/2462 (1.4) | 102/2154 (4.7) | <0.001 |
 Hyperlipidemia | 705/12,774 (5.5) | 5419/9195 (58.9) | 2342/3328 (70.4) | 865/2647 (32.7) | 2148/2462 (87.2) | 1595/2154 (74.0) | <0.001 |
 Hyperthyroidism | 308/12,774 (2.4) | 268/9195 (2.9) | 59/3328 (1.8) | 37/2647 (1.4) | 59/2462 (2.4) | 149/2154 (6.9) | <0.001 |
 Obesity | 1840/12,774 (14.4) | 5417/9195 (58.9) | 152/3328 (4.6) | 181/2647 (6.8) | 2462/2462 (100.0) | 518/2154 (24.0) | <0.001 |
 Gastrointestinal diseases | 1073/12,774 (8.4) | 834/9195 (9.1) | 73/3328 (2.2) | 275/2647 (10.4) | 508/2462 (20.6) | 1590/2154 (73.8) | <0.001 |
 Neurologic disease | 72/12,774 (0.6) | 44/9195 (0.5) | 207/3328 (6.2) | 577/2647 (21.8) | 121/2462 (4.9) | 253/2154 (11.7) | <0.001 |
 Previous VTE | 154/12,774 (1.2) | 89/9195 (1.0) | 46/3328 (1.4) | 56/2647 (2.1) | 97/2462 (3.9) | 110/2154 (5.1) | <0.001 |
Risk Scores | Â | Â | Â | Â | Â | Â | Â |
 CHA2DS2-VASc, median [IQR] | 2.00 [2.00, 3.00] | 3.00 [2.00, 4.00] | 4.00 [3.00, 5.00] | 4.00 [3.00, 5.00] | 4.00 [3.00, 5.00] | 4.00 [3.00, 5.00] | <0.001 |
 HAS-BLED, median [IQR] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 2.00 [1.00, 2.00] | 2.00 [1.00, 3.00] | 1.00 [1.00, 2.00] | 2.00 [1.00, 3.00] | <0.001 |